Skip to main content

Peer Review reports

From: An economic evaluation of cabazitaxel versus a second androgen receptor-targeted agent (ARTA) for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel and an ARTA: the United States payer perspective

Original Submission
11 Oct 2021 Submitted Original manuscript
6 Dec 2021 Reviewed Reviewer Report
14 Mar 2022 Reviewed Reviewer Report
7 Apr 2022 Reviewed Reviewer Report
16 May 2022 Reviewed Reviewer Report
15 Jun 2022 Author responded Author comments - Alicia K Morgans
Resubmission - Version 2
15 Jun 2022 Submitted Manuscript version 2
27 Jun 2022 Editorially accepted
14 Jul 2022 Article published 10.1186/s12913-022-08274-x

You can find further information about peer review here.

Back to article page